Novo Nordisk A/S $NVO Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 6.7% during the first quarter, HoldingsChannel reports. The institutional investor owned 3,397,121 shares of the company’s stock after buying an additional 213,443 shares during the quarter. Renaissance Technologies LLC’s holdings in Novo Nordisk A/S were worth $124,844,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $25,000. Scarborough Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the first quarter valued at approximately $26,000. WealthCollab LLC boosted its stake in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $28,000. Finally, Maseco LLP purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth approximately $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $48.76 on Friday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a market cap of $217.71 billion, a PE ratio of 11.45, a P/E/G ratio of 4.39 and a beta of 0.77. The stock has a 50 day moving average price of $46.36 and a 200 day moving average price of $45.74.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts expect that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on NVO. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.